Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)

NCT02020707 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02020707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02020707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
February 24, 2014
Completion date
July 18, 2024
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosarcoma, cervical adenosquamous carcinoma, cervical carcinosarcoma, cervical squamous cell carcinoma, clinical stage iv cutaneous melanoma ajcc v8, endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed cell adenocarcinoma, endometrial mucinous adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, fallopian tube adenocarcinoma, fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube squamous cell carcinoma, fallopian tube transitional cell carcinoma, fallopian tube undifferentiated carcinoma, malignant female reproductive system neoplasm, malignant ovarian clear cell tumor, malignant ovarian endometrioid tumor, malignant ovarian epithelial tumor, malignant ovarian mucinous tumor, malignant peritoneal neoplasm, malignant solid neoplasm, ovarian carcinosarcoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian high grade serous adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, ovarian undifferentiated carcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, platinum-sensitive ovarian carcinoma, primary peritoneal carcinosarcoma, primary peritoneal clear cell adenocarcinoma, primary peritoneal serous adenocarcinoma, primary peritoneal transitional cell carcinoma, primary peritoneal undifferentiated carcinoma, unresectable melanoma, uterine corpus carcinosarcoma